The U.S. Patent Office has issued a patent to Regenexx Corporation which teaches new compositions and methods of promoting the implantation and engraftment of stem cells.
New Patent Issued for Orthopedic Stem Cell Procedures
1 min read Premium comments
Secondary
The foundation for this new patent is the fact that tissue repair in vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking.
Regenexx’s new patent teaches compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may well be demonstrating in vitro abilities to expand autologous tissue repair cells.
This patent compliments Regenexx’s same-day cell procedure which has been used to treat joint injuries, spine pain ad degenerative conditions such as osteoarthritis.
Company CEO Christopher Centeno, M.D. said: “Consider this a patent on the use of a ’till the soil’ injection before you plant the seeds (stem cells).” According to a company statement, the patent is key to protecting Regenexx intellectual property as it relates to the company’s proprietary same-day stem cell procedure for orthopedic conditions.
According to the company, Regenexx has published approximately 33% of the world’s peer-reviewed research on the use of stem cells for treating orthopedic conditions.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.